CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 452 enrolled
Drug / intervention
Lopinavir/Ritonavir 400 mg/100 mg +1 moredrug
Likely dose
Lopinavir/Ritonavir 400 mg/100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04372628
NCT04372628Phase 2Completed
CompareCT.gov

Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19

Vanderbilt University Medical Center·interventional·Posted May 4, 2020·Updated Feb 28, 2024

In Brief

A Phase 2 clinical trial evaluating Lopinavir/Ritonavir 400 mg/100 mg and Placebo for COVID-19. Completed, enrolled 452 participants across 6 sites.

Detailed Summary

Blinded, multicenter, placebo-controlled, randomized clinical trial evaluating lopinavir/ritonavir vs placebo in early outpatient treatment of adults with COVID-19

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsAbbVie

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 4, 2020
Enrollment StartJun 1, 2020
Primary CompletionDec 16, 2021
Study CompletionJan 18, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.2 years ago

Interventions

Lopinavir/Ritonavir 400 mg/100 mgdrug

Lopinavir/Ritonavir tablets

Placeboother

Unmatched placebo